OBJECTIVE: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). METHOD:Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6 weeks each, separated by 1-week washout. Slopes for each condition were compared by paired t test. RESULTS:In 2004-2005, 12 boys and 4 girls (7 with autistic disorder, 1 Asperger's, 8 pervasive developmental disorder not otherwise specified) all completed at least 3 weeks of each condition. On the primary outcome, the Hyperactivity subscale of the Aberrant Behavior Checklist, ATX was superior to placebo (p =.043, effect size d = 0.90). It was also superior on a 0 to 3 rating of nine DSM-IV ADHD hyperactive/impulsive symptoms (p =.005, d = 1.27), but missed significance on nine inattentive symptoms (p =.053, d= 0.89). Nine subjects responded to ATX, four to placebo (25% improvement on the Hyperactivity subscale plus Clinical Global Impressions-Improvement of 1-2. One was rehospitalized for recurrent violence on ATX. Adverse events were otherwise tolerable, with no tendency to stereotypy. CONCLUSIONS:ATX appears safe and effective for treating hyperactivity in some children with autism spectrum disorders. The effect appears as large as in a multisite methylphenidate trial in the same population, with fewer intolerable side effects. Further study in autism spectrum disorders is indicated.
RCT Entities:
OBJECTIVE: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). METHOD:Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6 weeks each, separated by 1-week washout. Slopes for each condition were compared by paired t test. RESULTS: In 2004-2005, 12 boys and 4 girls (7 with autistic disorder, 1 Asperger's, 8 pervasive developmental disorder not otherwise specified) all completed at least 3 weeks of each condition. On the primary outcome, the Hyperactivity subscale of the Aberrant Behavior Checklist, ATX was superior to placebo (p =.043, effect size d = 0.90). It was also superior on a 0 to 3 rating of nine DSM-IV ADHD hyperactive/impulsive symptoms (p =.005, d = 1.27), but missed significance on nine inattentive symptoms (p =.053, d= 0.89). Nine subjects responded to ATX, four to placebo (25% improvement on the Hyperactivity subscale plus Clinical Global Impressions-Improvement of 1-2. One was rehospitalized for recurrent violence on ATX. Adverse events were otherwise tolerable, with no tendency to stereotypy. CONCLUSIONS:ATX appears safe and effective for treating hyperactivity in some children with autism spectrum disorders. The effect appears as large as in a multisite methylphenidate trial in the same population, with fewer intolerable side effects. Further study in autism spectrum disorders is indicated.
Authors: Eric A Storch; Elysse B Arnold; Anna M Jones; Chelsea M Ale; Jeffrey J Wood; Jill Ehrenreich-May; Adam B Lewin; P Jane Mutch; Tanya K Murphy Journal: Child Psychiatry Hum Dev Date: 2012-10
Authors: Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-09-03 Impact factor: 8.829
Authors: Blythe A Corbett; Laura J Constantine; Robert Hendren; David Rocke; Sally Ozonoff Journal: Psychiatry Res Date: 2009-03-12 Impact factor: 3.222
Authors: Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle Journal: Expert Opin Emerg Drugs Date: 2010-09 Impact factor: 4.191
Authors: Rameshwari V Tumuluru; Patricia Corbett-Dick; Michael G Aman; Tristram Smith; L Eugene Arnold; Xueliang Pan; Kristin A Buchan-Page; Nicole V Brown; Melissa M Ryan; Susan L Hyman; Jessica Hellings; Craig Williams; Jill A Hollway; Luc Lecavalier; Robert R Rice; Sarah McAuliffe-Bellin; Benjamin L Handen Journal: J Child Adolesc Psychopharmacol Date: 2017-05-16 Impact factor: 2.576